SynthesisEuropean journal of clinical pharmacology2020
Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies.
Synthesis in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Proton Pump Inhibitor Use and Risk of Dementia: An Umbrella Review of Systematic Reviews and Meta-Analyses.Digestive diseases and sciences · 2026Pooled it
- Systemic medications and dementia risk: a systematic umbrella review.Molecular psychiatry · 2025Pooled it
- A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer's disease and gastrointestinal tract disorders.Communications biology · 2022Pooled it
- Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.Journal of cancer research and clinical oncology · 2021Pooled it
- The impact of proton pump inhibitors on brain health based on cross-sectional findings from the Rhineland Study.Scientific reports · 2024Article
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates.Frontiers in aging neuroscience · 2024Article
- The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.Journal of cancer research and clinical oncology · 2023Article
- Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.Drugs & aging · 2023Article
- Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.Chonnam medical journal · 2023Review
- Proton pump inhibitors and dementia: what association?Dementia & neuropsychologia · 2023Review
- Potential risk of proton pump inhibitors for Parkinson's disease: A nationwide nested case-control study.PloS one · 2023Article
- Factors associated to potentially inappropriate prescribing in older patients according to STOPP/START criteria: MoPIM multicentre cohort study.BMC geriatrics · 2022Article
- Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions.Journal of asthma and allergy · 2022Review
- Gastric acid suppressants and cognitive decline in people with or without cognitive impairment.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Article
- A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data.Scientific reports · 2021Article
- The Janus-like Association between Proton Pump Inhibitors and Dementia.Current Alzheimer research · 2021Article
- Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer's Disease.Current neuropharmacology · 2021Review
- Proton Pump Inhibitors Increase the Risk of Autoimmune Diseases: A Nationwide Cohort Study.Frontiers in immunology · 2021Observational
- Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to explore the relationship between proton pump inhibitors use and the risk of dementia.
methodsA comprehensive literature search was conducted in English and Chinese databases from origination to December 2018. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with a random-effects model. Subgroup analyses and sensitivity analyses were also conducted. Cochran's Q test and the I
resultsSix studies were included, which contained a total of 166,146 participants. The overall result demonstrated a significant increase in dementia risk with proton pump inhibitors use (HR = 1.29, 95% CI = 1.12-1.49). In subgroup analyses, a significant association was detected between proton pump inhibitors use and the risk of dementia in Europe (HR = 1.46, 95% CI = 1.23-1.73) and among participants aged ≥ 65 years (HR = 1.39, 95% CI = 1.17-1.65). For the factor follow-up time ≥ 5 years, the pooled HR was 1.28 (95% CI = 1.12-1.46), demonstrating a 1.28-fold increase in the risk of dementia among proton pump inhibitors users. In the case of regional impact, participants from Europe showed an overall pooled HR estimate of 1.46 (95% CI = 1.23-1.73). There was no evidence of publication bias.
conclusionsThe overall result of this meta-analysis supports the hypothesis that proton pump inhibitors increase the risk of dementia. Furthermore, high-quality cohort studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.